Rivulet Media Inc (fka RIVU)

[Awchiro]

It's Also interesting that they anticipate filing IND and starting clinical trials for Cancer therapy both in Q4. Are they kidding themselves or do they anticipate a much smoother IND process? For HemeXcellarate , they filed IND in Q2 and is expecting to start in Q4. Why the difference? It might be due to the poor treatment option currently available, as Herceptin seems to be the only option and barely works, yet makes so much money. With such a low bar to clear, I am definitely optimistic about the cancer program. And the time frames in the PR almost seems like it neglects any chance of orphan drug status or fast track approval. That's almost the wild card, as any designation like that for either programs would explode this stock. All this and under 5 mm market cap. Ridiculously undervalued.